chronic diabetes News
-
2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and ...
-
Smart Home Lab - a Helpful Alternative to a Physician’s Office
What if the laboratory came home to you? Latest since the corona pandemic, the subject of “selftests” and “rapid tests” has finally reached a broad public. While previously it was more of a topic for chronic patients (e.g. diabetics) or for occasional tests (e.g. pregnancy test), we now see a clear trend. The determination of own body values, disease ...
-
AOTI Receives China FDA Approval for Topical Wound Oxygen (TWO2) Therapy Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have ...
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Showcase
AARP Names Its Innovator in Aging Prize Winner
En español | A wristband that helps you cool off or warm up quickly, offering relief from hot flashes or increasing your comfort, won AARP’s Innovator in Aging prize Tuesday morning. AARP CEO Jo Ann Jenkins presented the award to the company, Embr Labs, for its Wave device during a live segment on Good Morning America. The advocacy group for older adults increasingly is looking to ...
By Aidar Health
-
Novo Nordisk announces settlement of securities lawsuit in Denmark
Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs. The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make ...
-
Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax ...
-
Bayer receives approval in Japan for Kerendia (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetes
Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure or premature death Kerendia (finerenone) is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) outcomes in patients with CKD and T2D The approval is based on the ...
By Bayer AG
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
Impact of antidiabetic treatments must be taken into account in studying the gut microbiota
Research on gut microbiota (bacteria of the digestive tract) has for some years greatly contributed to advancing medical science. Within an international consortium, INRA scientists along with foreign colleagues have shown the impact of the antidiabetic treatment metformin on the gut microbiota of Type 2 Diabetes patients (T2D). The results, published in Nature on December 2, stress that the ...
-
Exercising everyday keeps the doctor away
The health benefits of regular exercise are well known and are commonly featured in public awareness campaigns. Now, recent research has revealed just how dangerous a lack of physical activity can be to the human body. One of the most repeated pieces of medical advice given today is that people should do at least 30 minutes of moderate exercise five days a week. This regular activity is thought ...
-
Bayer’s new treatment Kerendia (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes
Kerendia is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) The approval is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of Kerendia on kidney and CV outcomes in ...
By Bayer AG
-
Novo Nordisk praises historic declaration to fight diabetes
On December 13, 2010, twenty-two countries from the Middle East and Northern Africa (MENA) and five international organisations agreed on the "Dubai Declaration on Diabetes and Chronic Non-Communicable Diseases in the Middle East and Northern Africa Region." The agreement was the culmination of the Novo Nordisk sponsored MENA Diabetes Leadership Forum held on December 12-13 in Dubai. "We are ...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with ...
By Bayer AG
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients ...
By Bayer AG
-
Kerendia (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure and premature death Kerendia (finerenone) is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) outcomes in patients with CKD associated with T2D The approval in China ...
By Bayer AG
-
Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) An exploratory ...
By Bayer AG
-
Second grant win to research Peritoneal Dialysis indication
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
-
Glooko Webinar with Fierce Healthcare Covers Promising Outlook for Telehealth and Remote Patient Monitoring
Telehealth and remote patient monitoring (RPM) have been found to effectively manage patient and population health. During a webinar with Fierce Healthcare last month, Glooko CEO Russ Johannesson joined Tufia Haddad, MD, Chair of Practice Innovation and Platform, The Mayo Clinic and Professor Carri W. Chan, PhD, Professor, Division of Decision, Risk and Operations and Faculty Director, ...
By Glooko, Inc.
-
Merck significantly expands its patient assistance program offerings to provide access to more medicines for people in need
Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps™ patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines. The Merck Helps programs provide Merck ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you